SEC Form 4 · accession 0000899243-18-028970
AMEDISYS INC · AMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Gerard
Officer — Chief Operating Officer
Period of report
Nov 9, 2018
Accepted (ET)
Nov 14, 2018 · 9:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000896262
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 9, 2018 | M | 7,892 | $46.35 | A | 29,429 | D | |
| Common StockF1 | Nov 9, 2018 | S | 5,600 | $118.64 | D | 23,829 | D | |
| Common StockF2 | Nov 9, 2018 | S | 2,292 | $119.94 | D | 21,537 | D | |
| Common StockF3 | holding | — | — | — | 211 | I | Through 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $46.35 | Nov 9, 2018 | M | 7,892 | D | — | Jan 20, 2027 | Common Stock | 7,892 | 23,675 | D |
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.30 to $119.09, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.52 to $120.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3The information in this report is based on a plan statement dated as of September 30, 2018.
- F4On January 20, 2017, the reporting person was granted an option to purchase 31,567 shares of common stock. The option vested as to 7,892 shares on January 20, 2018, and the remaining 23,675 options vest in equal installments on each of January 20, 2019, January 20, 2020 and January 20, 2021, provided that the reporting person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the stock option.